[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366063-105":59,"doc-detail-366063-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","human-endogenous-retrovirus-k-envelope-protein-is-aberrantly-expressed-in-serous-ovarian-cancer-and-promotes-chemosensitivity-via-nf-bp-glycoprotein-pathway-inhibition","Human endogenous retrovirus-K envelope protein is aberrantly expressed in serous ovarian cancer and promotes chemosensitivity via NF-κB/P-glycoprotein pathway inhibition","","This study investigates whether human endogenous retrovirus-K (HERV-K) envelope (env) protein is expressed in serous ovarian cancer and how it relates to clinical behavior and drug response. HERV-K env expression was examined across normal, benign, borderline, and cancerous serous ovarian tissues using immunohistochemistry and digital pathology. Transcriptomes, antiproliferative effects, and chemoresponsiveness were evaluated with RT-PCR/sequencing, MTT/colony assays, and paclitaxel resistance models. HERV-K env associated with chemosensitivity and suppressed NF-κB/P-glycoprotein signaling, suggesting therapeutic potential for chemoresistant ovarian cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/human-endogenous-retrovirus-k-envelope-protein-is-aberrantly-expressed-in-serous-ovarian-cancer-and-promotes-chemosensitivity-via-nf-bp-glycoprotein-pathway-inhibition/366063/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/human-endogenous-retrovirus-k-envelope-protein-is-aberrantly-expressed-in-serous-ovarian-cancer-and-promotes-chemosensitivity-via-nf-bp-glycoprotein-pathway-inhibition/366063.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was HERV-K env expression measured in ovarian tissues?","Question",{"text":112,"@type":113},"HERV-K env protein expression was assessed using immunohistochemistry and QuPath digital analysis across normal, benign, borderline, and serous cancer tissues.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What proportion of serous carcinomas and borderline tumors showed HERV-K env expression?",{"text":117,"@type":113},"HERV-K env was detected in 37.5% (27 of 72) of serous carcinomas and 61.5% (8 of 13) of borderline tumors, while it was absent in normal ovarian epithelia and benign tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"How does HERV-K env influence chemoresistance to paclitaxel?",{"text":121,"@type":113},"Forced expression of HERV-K env in paclitaxel-resistant cells suppressed proliferation and resensitized cells to paclitaxel by inhibiting NF-κB/P-glycoprotein signaling; siRNA knockdown restored paclitaxel resistance via recovered NF-κB/P-glycoprotein activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366063,1790210880,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Nguyen et al. Journal of Ovarian Research (2025) 18:146 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-025-01722-2](https://doi.org/10.1186/s13048-025-01722-2)  \nRESEARCH Open Access  \nHuman endogenous retrovirus-K envelope protein is aberrantly expressed in serous ovarian cancer and promotes chemosensitivity via NF-κB/P-glycoprotein pathway inhibition  \nQue Thanh Thanh Nguyen 1†, Soo-Gui Shin 1†, TraTranThu Nguyen 1, Kyoung Yul Lee2, Michael McClelland3 and Eun-Ju Lee 1,4*  \nAbstract  \nBackground Approximately 100,000 human endogenous retroviruses (HERV) are integrated into the human genome. Most HERVs are not expressed; however, transcription within the family HERV-K, a class II beta-retrovirus, occurs in specific cancers. Herein, we investigated HERV-K env protein expression and its clinical and molecular significance in serous ovarian cancer.  \nMethods Protein expression was assessed via immunohistochemistry and QuPath digital analysis in 24 normal, 10 benign, 13 borderline and 72 cancerous serous ovarian tissues. Clinicopathological parameters were obtained from medical records. Transcriptomes were evaluated using strand-specific reverse transcription-PCR and sequencing. Antiproliferative activities were explored using MTT and colony formation assays. A stable transfection expression system and siRNA gene silencing were used. Resistant cell lines were established using the paclitaxel concentration gradient method and chemoresponsiveness was evaluated by measuring the IC50.  \nResults HERV-K env was absent in normal ovarian epithelia and benign tumors but was detected in 37. 5%(27 of 72) of serous carcinomas and 61. 5%(8 of 13) of borderline tumors. Unexpectedly, HERV-K env was observed in lymphocytes only in a subset of HERV-K env-positive tumors: 18 of 27 invasive and 1 of 8 borderline tumors. HERV-Kenv-positivity was significantly associated with chemosensitivity, although the prognosis was unaffected. HERV-K type I (K101, K102, and K103) and II (K108 and K115) were transcribed in cultured ovarian cancer cells and tissues but not in their paclitaxel-resistant derivatives. Forced expression of HERV-K env in paclitaxel-resistant cells suppressed cellular  \n†Que Thanh Thanh Nguyen and Soo-Gui Shin contributed equally to this work.  \n*Correspondence: Eun-Ju Lee [ejlee@cau.ac.kr](ejlee@cau.ac.kr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nNguyen et al. Journal of Ovarian Research (2025) 18:146 Page 2 of 13  \nproliferation and resensitized cells to paclitaxel by inhibiting NF-κB/P-glycoprotein. siRNA-mediated HERV-K env knockdown restored paclitaxel-resistance by recovering NF-κB/P-glycoprotein.  \nConclusion HERV-K env was expressed in serous ovarian carcinoma and significantly associated with chemosensitivity. HERV-K env attenuated NF-κB/P-glycoprotein, a mechanism of chemoresistance. Hence, it could have therapeutic ","cbCaiqBkZyhbVGHm","https://ap.wps.com/l/cbCaiqBkZyhbVGHm","pdf",4183943,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background","[{\"question\":\"How was HERV-K env expression measured in ovarian tissues?\",\"answer\":\"HERV-K env protein expression was assessed using immunohistochemistry and QuPath digital analysis across normal, benign, borderline, and serous cancer tissues.\"},{\"question\":\"What proportion of serous carcinomas and borderline tumors showed HERV-K env expression?\",\"answer\":\"HERV-K env was detected in 37.5% (27 of 72) of serous carcinomas and 61.5% (8 of 13) of borderline tumors, while it was absent in normal ovarian epithelia and benign tumors.\"},{\"question\":\"How does HERV-K env influence chemoresistance to paclitaxel?\",\"answer\":\"Forced expression of HERV-K env in paclitaxel-resistant cells suppressed proliferation and resensitized cells to paclitaxel by inhibiting NF-κB/P-glycoprotein signaling; siRNA knockdown restored paclitaxel resistance via recovered NF-κB/P-glycoprotein activity.\"}]","Human endogenous retrovirus-K envelope protein is aberrantly expressed in serous ovarian cancer and promotes chemosensitivity via NF-κB/P-glycoprotein pathway inhibition | PDF",1790163728,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4dfa05232c3605cb382f0d93cd50ae0.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba01e3ed4832910e18badd3d1ed51f02.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9da77199a47e4ff8b3d246d858388785.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70e7e006db84994a6f56a4facb7881fc.webp",980,1306]